 |
|
|
| |
Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Plus Darunavir (DRV) in Treatment-Experienced HIV-1-Infected Adults (NCT01968551)
|
| |
| |
Reported by Jules Levin
IDSA 2015 Oct 7-11 San Diego, CA
Gregory Huhn,1 Pablo Tebas,2 Joel Gallant,3 Timothy Wilkin,4 Andrew Cheng,5 Mingjin Yan,5 Christian Callebaut,5 Marshall Fordyce,5 Moupali Das,5 Scott McCallister5
1The Ruth M Rothstein CORE Center, Chicago, IL; 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; 3Southwest CARE Center, Santa Fe, NM; 4Division of Infectious Diseases, Weill Cornell Medical College, New York, NY; 5Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
